… effects and risks of prescribed antipsychotics, stimulants, antidepressants, anxiolytics, and … an “overprescription” of psychiatric drugs.  Meggan Coleman, the national … veterans before starting long-term treatment with psychiatric medications.” Despite …

… side effects of certain drugs before they are prescribed. … duplicative prescription. Many prescribed drugs—such as antipsychotics, stimulants, antidepressants, anxiolytics … consent is also needed for antipsychotics, stimulants, antidepressants, anxiolytics, …

… biggest barriers to staying on antipsychotic treatment in young people, and researchers … -cost diabetes drug, produced a modest but steady reduction in antipsychotic-related … drug that, in several small trials, reduced weight gain linked to antipsychotics …

… disorders. Individuals receiving second-generation antipsychotics (SGAs) are known to face … agonist (GLP-1RA) early in treatment could counteract these metabolic disturbances … 26 weeks, alongside their existing antipsychotic therapy. The primary focus of …

… said. Medicare Part D, Medicaid pharmacy claims and other outpatient or … done to combat underreporting of antipsychotic use and overreporting of schizophrenia … also clinically appropriate indications for antipsychotics. One addition to exclusions was …

… sometimes coprescribed with second-generation antipsychotics (SGA) to help … from the College of Pharmacy at the University of … of metformin with SGA drugs was associated with improved … basis or as a treatment for [antipsychotic-induced weight gain].” The …

… the added drugs were antidepressants or antipsychotics—agents associated … antianxiety drugs, 465,599 were put on antipsychotics, and … with mind-altering antidepressants, antipsychotics, or sedative-hypnotics, … under the guise of treatment,” Eastgate said. “This …

… in schizophrenia, exacerbated by antipsychotic-induced weight gain and poor … focusing on dietary interventions and pharmacological treatments. As the Voice of Psychiatry … Johnson & Johnson supplemental New Drug Application for esketamine (Spravato) …

… to the Food and Drug Administration for clearance. Developed … is a 16-week treatment that adapts key elements … as an adjunct to antipsychotic drug treatment. Schizophrenia affects millions of … control app. Importantly, the treatment met its primary endpoint …